Shots:

• Urology San Antonio joins Anixa's ongoing Cchek prostate cancer study to advance Ccheck liquid biopsy technology toward commercialization
• The collaboration will improve the care of patients with prostate cancer with the commercialization of the technology utilizing flow cytometry coupled with AI to detect cancer early- making a significant impact on the overall testing paradigm
• Cchek is an early cancer detection technology act by measuring a patient's immunological response to a malignancy- analyzing immune system cells in peripheral blood. The patient’s cancer status can be detected via simple blood draw eliminating the need for a biopsy with its expected commercial launch by the year-end 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology